Recent evidence suggests that reproductive ste roids are important players in shaping stroke outcome and ce rebrovascular pathophysiologic features, Although women are at lower risk for stroke than men, this native protection is lost in the postmenopausal years, Therefore, aging women sustain a large burden for stroke, contrary to a popular misconception that cancer is the main killer of women, Further, the value of hormone replacement therapy in stroke prevention or in im proving outcome remains controversiaL Estrogen has been the best studied of the sex steroids in both laboratory and clinical settings and is considered increasingly to be an endogenous neuroprotective agent. A growing number of studies demon strate that exogenous estradiol reduces tissue damage resulting STROKE IN WOMEN VERSUS MEN: RISKS AND OUTCOMES
Overall incidence of stroke is uniformly higher in men than in women in all countries (Sudlow and Warlow, 1997) , but increases with age in both sexes (Prencipe et aI., 1997) and strongly reflects ethnic/racial background (Kuhlemeier and Stients, 1994; Morgenstern et aI., 1997) (Fig, 1 ). Stroke is rare in women during the reproductive years, and in young women (15 to 44 years of age) is predominately embolic in origin (Carolei et aI., 1993) or is caused by subarachnoid hemorrhage (Petitti et aL, 1996 (Petitti et aL, , 1997 . The latter is the only subtype of stroke more common in women than men, In longitudinal studies, women sustain fewer strokes of all types than age matched men (incidence ratio as high as 1: 1,35) (Kurtzke, 1985) , The importance of female sex steroids from experimental ischemic stroke in both sexes, This new concept suggests that dissecting interactions between estrogen and cerebral ischemia will yield novel insights into generalized cellular mechanisms of injury, Less is known about estrogen's undesirable effects in brain, for example, the potential for in creasing seizure susceptibility and migraine, This review sum marizes gender-specific aspects of clinical and experimental stroke and results of estrogen treatment on outcome in animal models of cerebral ischemia, and briefly discusses potential vascular and parenchymal mechanisms by which estrogen sal vages brain, Key Words: Estrogen-Stroke-Cerebral isch emia-Reproductive steroids-Neuroprotection, to this relative protection is not known, but male-female differences weaken in aged subjects (Manolio et aI., 1996) . For example, gender effects in the Framingham Study are most striking in subjects within the 45-to 54-year age cohort (combined incidence of stroke and transient ischemic attack 2.1 versus 1.2 per 1,000 in men and women, respectively), but equalize in the 55-to 64year-old cohort (Wolf, 1990) . Alternatively, others report higher incidence of intracerebral hemorrhage and corti cal infarction in men versus women, trends which persist well beyond the menopause (Giroud et aI., 1991) .
Known risk factors for ischemic stroke are similar in men and women; most epidemiologic studies do not identify significant differences in relative risks. Recent studies found no sex differences in the importance of hypertension as a risk factor (Hayes and Taler, 1998) , although diabetes and atrial fibrillation may be larger risk factors in women (Wolf et aL, 1991) . These state ments do not include relative risks to women younger than 50 years of age, including pregnancy, migraine, and oral contraceptives (for review, see Bousser, 1999) . Fur thermore, atherosclerotic disease may progress more slowly and to a lesser degree in women versus men. In a study of 5,033 consecutive autopsies, women demon strated strikingly less cerebral atherosclerosis relative to men until age 65 years; then lesion frequency equaled Age-and sex-standardized annual incidence per 100,000 of all types of stroke combined for the group aged 45 to 84 years and with men and women considered separately. Studies are arranged in ascending order of age-and sex-standardized incidence rates. The numbers shown are point estimates, and the error bars are 95% confidence intervals. Reprinted with permission from Sudlow and Warlow, 1997. that of men (Flora et a\., 1968) . Consistent sex-linked differences also have been reported in carotid and verte bral arterial disease (Caplan et aI., 1986) .
Gender may have an influence not just on the risk of having a stroke (stroke proneness or latency to stroke) but also on the severity of damage induced by the stroke (stroke sensitivity). Although lifetime risk of stroke is higher in men, mortality associated with stroke is higher in women. However, this is most likely because of their lO-year-longer life expectancy and the older age at which clinical disease is manifested. Interactions with ethnic background may influence these data (Morgen stern, 1997) . However, findings from the World Health Organization Monitoring of Trends and Determinants in Cardiovascular Disease (WHO MONICA project) dem onstrate that average case-fatality rates are higher in women than men in 12117 European and Asian countries studied (WHO MONICA Project, 1997) . Further, current projections suggest a higher likelihood of death from stroke for women (16% of the population) than for men (8%) (Bonita, 1992) . Gender-based recovery from stroke has not been heavily studied, but functional impairment (Wyller et aI., 1997) and depression (Kotila et aI., 1998) appear greater in women.
Since most strokes occur in postmenopausal women, there has been much interest in determining whether the potential for ovarian hormone replacement to improve coronary heart disease is equally valid in reducing cere brovascular disease. Although detailed analysis is be- Vol. 20. No. 4, 2000 yond the scope of the present review, the efficacy of estrogen replacement therapy (ERT) or combined hor mone therapy (HRT) with estrogen and a progestin re mains unproven for stroke. In part, there are large diffi culties in interpreting or comparing results from previous studies because they (1) are cohort or case-control ob servational studies, not randomized trials; (2) use a va riety of estrogen and progesterone preparations or com binations; (3) vary in sampling women who are "ever users" or "current users" of HRT; (4) may be unavoid ably biased by the observation that women likely to seek HRT tend to be healthier in general; and (5) vary in the stratification for SUbtype of stroke, such as subarachnoid or intracerebral hemorrhage. Some clarity may be ob tained as the results of ongoing randomized studies emerge, including the Women's Heath Initiative to be reported at approximately year 2006 and a study of sec ondary prevention, the Women's Estrogen for Stroke Trial (WEST) to be published in the year 2000.
Most studies examine the effects of unopposed conju gated equine estrogen, and more recently, effects of es trogen plus a progestin, for example, medroxyprogester one acetate (Falkeborn et aI., 1993; Grodstein et a\., 1996 Grodstein et a\., , 1997 Schairer et aI., 1997; Petitti et aI., 1998) . Grady et aI. (1992) found little consistent evidence in an early and comprehensive literature review that ERT re duced stroke risk, although estrogen use was associated with reduced death from stroke. Subsequent studies pro vide further data for effect of treatment on risk and mor-tality, but the overall picture remains inconsistent. Like wise, ERT has been reported to increase (Wilson et aI., 1985) , decrease (Finucane et aI., 1993; Lafferty and Fiske, 1994) or have no effect (Pederson et aI., 1997; Petitti et al., 1998) on stroke risk. Combined estrogen progestin treatment also has produced varied results: some studies report risk reduction for intracerebral hem orrhage (Schairer et al.. 1997) or stroke of mUltiple eti ologies (Falkeborn et al., 1993) , whereas others show no effect (Grodstein et al., 1996) , particularly in nonfatal thromboembolic, hemorrhagic (Pederson et aI., 1997) , and ischemic stroke (Petitti et aI., 1998) . In contrast, available data suggest that ERT (Henderson et aI., 1991; Grady et ai., 1992; Sourander et ai., 1998) and HRT (Finucane et ai., 1993; Grodstein et al., 1997) reduce mortality from stroke in women when it does occur.
In summary, women may be "protected" from stroke, but this is restricted by factors that involve reproductive age and ethnic or genetic background. When stroke oc curs in the postmenopausal woman, mortality may be higher relative to the male, although this observation is based on highly limited data. The value of exogenous hormone replacement in improving risk and outcome is therefore unclear. However, most reports suggest that fatal strokes are reduced.
GENDER AND EXPERIMENTAL STROKE
Given the complexity of the clinical observations, sev eral laboratories have used animal models to study gen der influences on ischemic brain injury. In addition, rat strains developed by selective breeding programs to dis play increased stroke proneness and stroke sensitivity (spontaneously hypertensive rat-stroke prone [SHR-SP]) have been used to evaluate gender-genetic interactions. These data establish a foundation or rationale for subse quent studies of ovarian steroids as neuroprotective agents.
Numerous studies demonstrate gender-specific re sponses to experimental cerebral ischemia, head trauma Emerson et al., 1993; Roof et al., 1993) , and hypoxic brain damage (Stupfel et ai., 1979; Saiyed and Riker, 1993) . Early studies of forebrain ischemia in gerbils in dicate that females sustained lower mortality and less neuronal damage after unilateral carotid occlusion than males (pay an and Conard, 1977; Hall et al., 1992) . The severity of c�rebral ischemia and the quality of reperfu sion were not different between the sexes. However, preservation of endogenous vitamin E was observed in females, suggesting an enhanced antioxidant capacity (Hall et ai., 1992) . Although gonadectomized animals were not evaluated in these studies, female resistance to ischemia was present only in animals receiving carotid ligation after sexual maturity (payan and Conard, 1977) . Subsequent studies in a range of different rat stroke models (direct or indirect middle cerebral artery occlu sion [MCAOl) have uniformly confirmed that histologic damage is less in female animals, sampled randomly across estrous cycle, than in age-matched males (Li et aI., 1996; Alkayed et ai., 1998a; Zhang et al., 1998) (Fig. 2A) . In an animal model of embolic stroke induced by photochemical irradiation of the common carotid artery, thromboembolism produced greater inflammatory cellu lar infiltrate, but less severe infarction, in female com pared with male rats (Li et ai., 1996) .
Evidence that reproductive steroids are key to the gen der differences comes from studies in gonadectomized animals. Using a reversible MCAO model, we have dem onstrated that both cortical and striatal infarct volumes are smaller in sexually mature female rats relative to their male or ovariectomized (OVX) female counterparts (Alkayed et al., 1998b ) ( Fig. 2A) . Estrogen seems to be the major hormonal player in these experiments because (I) estrogen levels were reduced in OVX female rats compared with those of the male, and (2) although pro gesterone was reduced relative to normal female values, plasma values remained higher than in the male.
The intluence of male sex hormone testosterone on cerebral ischemic damage is less clear. Like estrogen, testosterone is a vasodilator of some vascular beds, pos- Focal cerebral ischemia induced in males and females during metestrus in Wistar Kyoto (WKY; males n = 9, females n = 8) and spontaneously hypertensive stroke-prone rats (SHR-SP; males n = 8, females, n = 7). Cerebral ischemia was induced by a distal diathermy occlusion of the middle cerebral artery for 24 hours. Infarct volumes were measured in hematoxylin and eosin stained brain sections and expressed as a percentage of the ipsilateral hemisphere. Data are represented as mean ± SEM; ·sig nificant difference from male WKY (P < 0.05); ··significant differ ence from male SHR-SP (P= 0.01). Reprinted with permission from Carswell et ai., 1999a. sibly by a common mechanism involving vascular smooth muscle potassium channels (Yue et a!., 1995; Chou et a!., 1996) . Further, androgen receptors are pre sent in brain regions not associated with reproduction (Simerly et a!., 1990; Takeda et a!., 1990) . Loss of tes tosterone (castration) has been studied in relation to MCAO in two studies. In one, castration did not influ ence outcome to MCAO, suggesting a lack of influence of testosterone on outcome (Toung et a!., 1998) . The other report demonstrated a reduction in lesion size of 59% with castration, which was partially reversed by testosterone replacement, and concluded that testoster one had an adverse effect on outcome to ischemia (Hawk et a!., 1998) . Testosterone has been implicated as a risk factor for acute myocardial infarction (Phillips et a!., 1994) , altered lipid metabolism in young men (Hro madova et a!., 1991), and in cardiovascular collapse after trauma and hemorrhagic shock in animals (Remmers et a!., 1997) . Further study of the effects of testosterone on functional or histologic outcome and on intraischemic CBF are needed to resolve the importance of this hor mone in stroke.
Gender-genetic interactions
The SHR-SP strain, originally derived by selective breeding from the normotensive reference strain, the Wistar Kyoto rat (Okamoto et a!., 1974) , has a geneti cally determined increased sensitivity to experimental stroke (Coyle and Jokelainen, 1993; Gratton et a!., 1998; Alkayed et a!., 1998a; Carswell et a!., 1999a) (Fig. 2B) , as well as an increased incidence of spontaneous stroke (stroke proneness) and hypertension. In an early study, Vol. 20, No. 4. 2000 Yamori et a!. (1976) report that the incidence of spon taneous strokes was greater in male SHR-SP compared with female SHR-SP up to age 25 weeks. Female SHR-SP also had a longer life span and later onset of spontaneous stroke than males. Furthermore, estrogen pretreatment in castrated males decreased the incidence of spontaneous stroke, increased life span, and delayed hypertension relative to intact males, whereas androgen treatment in gonadectomized females reduced life span relative to intact females.
Female SHR-SP also demonstrate reduced infarct vol umes compared with SHR-SP males when taken at ran dom during the 4-to 5-day estrus cycle (Fig. 2B ). This situation is reversed when stroke is induced during met estrus (Carswell et a!., 1999a) (Fig. 3) , the stage in the cycle when estrogens and progesterone are at their low est levels in the circulation ( Fig. 4 ), suggesting that changes in the levels of sex hormones, even within the physiologic range of the estrus cycle, can alter stroke sensitivity. This seems particularly applicable in the SHR-SP since, in this strain, rats that have experimental stroke induced during metestrus sustain significantly greater infarct volumes compared with those occluded during proestrus (plasma estrogen at peak levels) (Car swell et a!., 1999b) ( Fig. 5 ). However, this was caused by improvement in CBF (see later section, "Vasodilation and Improved CBF?")
Notice that although gender-specific outcome after ce rebral ischemia has been repeatedly demonstrated in ro dents, there is a paucity of studies in higher order animal species where no data are available in models of isch emic, hemorrhagic, or thromboembolic stroke. A single study evaluates female versus male neurologic recovery at 24 hours after cardiac arrest in the dog (Zwemer et a!., 1997) . Systemic organ function was more impaired in females, but neurologic score was not different between sexes. Histologic injury was not measured, and one con founding variable in this study was the use of female dogs of varying reproductive states, including postpar tum and partially gonadectomized animals.
ESTROGEN TREATMENT IN

EXPERIMENTAL STROKE
If estrogen is a naturally occurring neuroprotectant, then treatment with physiologically relevant amounts of the steroid should improve outcome in estrogen-deficient brain. A mounting number of in vivo investigations sug gests that this hypothesis is correct (Table 1) (Hum et aI., 1995; Kondo et aI., 1997; Shi et aI., 1997; Sudo et aI., 1997; Chen et aI., 1998; Green et aI., 1998; Pelligrino et aI., 1998; Shi et aI., 1998; Wang et aI., 1999; Zhang et aI., 1998) . Critical considerations include the therapeutic range and treatment duration for efficacy, determination of effect in both sexes, estrogen's actions on the level of ischemic insult (i.e., flow-mediated effects) and on reper fusion, and efficacy in young mature versus postmeno pausal animals.
In most studies, 1713-estradiol has been the agent cho sen for the replacement paradigm, in part because the steroid is the predominant, biologically active estrogen in mammals. Since systemic estrogen levels were not mea sured or reported in all articles reviewed, some infer ences are needed to compare treatment effects from physiologic versus supraphysiologic doses. For point of reference, physiologic plasma 1713-estradiol levels, as re-ported in the rat, range between 10 and 30 pg/mL with peak levels during proestrus of 80 to 140 pg/mL. (Smith et aI., 1975; Butcher et aI., 1974; Nequin et aI., 1979) .
Effects of estrogen restoration have been most com prehensively studied in OVX female rodents (Table I) . Chronic treatment (with subcutaneous implants or daily injections) and acute treatment (with one-time infusion or injection) have been used. Investigations address ef ficacy in improving histologic, hemodynamic, or behav ioral outcomes after transient MCAO (Simpkins et aI., 1997; Zhang et aI., 1998; Dubal et aI., 1998; Rusa et aI., 1999) or global forebrain ischemia (Hum et aI., 1995; Ko ndo et aI., 1997; Pelligrino et al., 1998; Wang et aI., 1999) .
Histologic outcome
Women. In studies of chronic estrogen replacement after ovariectomy (approximately 1 week before isch emia), which produced physiologic plasma steroid lev els, tissue damage was uniformly decreased in global forebrain ischemia (Pelligrino et aI., 1998) and focal ischemia (Table 1) (Dubal et aI., 1998; Rusa et aI., 1999) . However, the therapeutic dose range was narrow, with beneficial effects decreasing as the dose and plasma es tradiol level increased upward within the physiologic range (Pelligrino et aI., 1998; Rusa et aI., 1999) . In con trast, high-dose implants of 1713-estradiol placed 24 hours before MCAO reduced infarction volume, suggest ing that short-term exposure to pharmacologic doses also can be beneficial (Table 1) (Simpkins et aI., 1997) . In addition, high doses of estrogen (plasma levels up to 25 to 28 times greater than in OVX females) have been shown to improve cognitive performance in the Morris water maze in OVX gerbils after bilateral carotid artery occlusion (Kondo et aI., 1997) .
Two studies indicate that estrogen must be delivered chronically before ischemia, rather than as a single in jection or subcutaneous implant at ischemic onset, to be effective in OVX females (Table 1) (Dubal et aI., 1998; Rusa et aI., 1999) . However, the study by Simpkins et aI., (1997) illustrates that a high dose 1713-estradiol injection before MCAO or at the onset of reperfusion can effec tively reduce infarction (Table 1) . A subsequent study from this same group demonstrates that 1713-estradiol injection within a more physiologically relevant range also produced a dose-dependent reduction in infarction, even when given at the onset of reperfusion (Zhang et aI., 1998) .
Men. An important question is whether exogenous es trogen also protects the male brain, interacting with tis sue not ordinarily exposed to cyclically high concentra tions of female reproductive steroids. Interactions be tween native testosterone and estrogen treatment have been examined, although in a limited manner, with some conflicting results. Several investigations in the male rat and gerbil confirm that preischemic estrogen, adminis tered either chronically or as a single injection, reduces tissue damage and functional deficits after both global Sudo et al., 1997) and focal (Hawk et al., 1998; Toung et al., 1998) ischemic insults. After transient forebrain ischemia, 17[3-estradiol, given over a wide range of concentrations, protects CAl neurons and improves performance in passive avoidance tasks in male gerbils (Sudo et al., 1997) . However, this study demonstrates a ceiling and loss of efficacy at ex treme doses (1.25 f-lg/day for 7 days through the lateral ventricle) and increasing mortality in some cases (Sudo et al., 1997) , but Chen et al. (1998) report no mortality problems with high doses (30 f-lg, intracerebroventricu lar) and suggest that high doses of l7[3-estradiol are re quired for neuroprotection (3 and 10 f-lg were not pro tective).
Doses yielding plasma estradiol levels that are physi ologic or supraphysiologic in the female rat are equally efficacious in males exposed to MCAO. Both chronic (7to lO-day subcutaneous) and acute (30-minute intrave nous) pretreatments significantly reduce infarct volume in intact male rats (Table 1) (Toung et al., 1998; Hawk et J Cereh Blood Flow Metab, Vol. 20. No. 4. 2000 a!., 1998), suggesting that nontranscriptional mecha nisms of action may be important in the male brain.
Estradiol treatment combined with castration is more complex. In one study, where castration did not influence infarct size, the addition of estrogen dose-dependently reduced the lesion to a similar extent as reported in non castrated males with normal testosterone levels (Toung et al., 1998) . However, in another study, castration per se reduced infarct size significantly, with estrogen pretreat ment producing no further reduction in infarct size ( Table 1) (Hawk et al., 1998) . Simultaneous testosterone and estradiol treatment in castrates resulted in an isch emic lesion intermediate between animals treated with either hormone alone (Hawk et al., 1998) . Because es tradiol treatment was accompanied by a decrease in tes tosterone levels in intact males, the authors conclude that estrogen protects the male brain by this means.
Further studies are required to evaluate estrogen testosterone interactions in cerebral ischemia and to rec oncile the experimental differences in the literature. The efficacy of estrogen administered during or after the ischemic insult has not been reported in male animals. Nevertheless, the data clearly show that estradiol reduces postischemic brain injury and functional deficits in intact male and in female rats.
Senescent animals. We also have examined stroke out comes in 16-month-old reproductively senescent male and female Wistar rats to test the hypothesis that gender differences are lost as endogenous hormone levels wane (Hum et aI., 1998; Alkayed et aI., 2000) . In aged ani mals, damage to the striatum and cortex after MCAO (2 hours of occlusion, 22 hours of reperfusion) was equiva lent in females and males (Fig. 6A ). This observation is consistent with the concept that endogenous ovarian ste roids are neuroprotective in stroke and the finding of higher stroke rates in postmenopausal versus premeno pausal women. When estrogen was restored in aged fe males using subcutaneous 1713-estradiol implant (25 fLg. 7 to 10 days' duration), infarction size was strikingly reduced in all brain regions examined, although the ef fect was particularly prominent in cortex ( Fig. 6B ). How ever, the neuroprotective mechanism is unlikely to be flow enhancement, since intraischemic regional CBF, as measured by 14 C iodoantipyrine, was not altered by es trogen treatment. These experiments in aged female Wistar rats demonstrate that the benefit of estrogen re placement is not restricted to young animals artificially deprived of ovarian steroid, since physiologic doses of 1713-estradiol also are neuroprotective in the postmeno pausal female brain.
To summarize these animal studies, estrogen is an ef fective neuroprotectant in both male and female brain, although the requisite dose and duration of steroid expo sure may differ between the sexes. Although these find ings suggest a plausible and novel clinical use for estro gen, numerous experiments are needed to determine fully the steroid's therapeutic window of activity and optimal dose-response relationships in stroke.
POTENTIAL MECHANISMS OF
ESTRADIOL-MEDIATED NEUROPROTECTION
Vasodilation and improved CBF?
Native estrogens or exogenous 1713-estradiol could act as direct vasodilators or through vasodilatory mediators Effects of estrogen (25-�g pellet, subcutaneously for 7 days, n = 9) and progesterone (10-mg pellet, subcutaneously for 7 days, n = 9) treat ments on total cortical and striatal infarcts after 2 hour intraluminal filament-induced ischemia plus 22 hours of reperfusion in reproduc tively senescent female rats (untreated female, n = 9). Infarct was identified in brain sections by TTC staining and expressed as a per centage of ipSilateral cerebral cortex or striatum. Data are represented as mean ± SEM; 'significant difference compared with untreated group (P < 0.05). AP, anteroposterior. Reprinted with permission from AI kayed et aI., 2000.
P. D. HURN AND f. M. MACRAE during ischemic stress. Numerous studies document va somotor effects of estrogen under nonischemic condi tions, and 17f3-estradio1 is a dilator of most vascular beds (for reviews see Mendelson and White et aI., 1995) . Early studies using 133 Xe inhalation method ologies show that absolute regional CBF was higher in women versus men, particularly in gray matter (Davis et aI., 1983; Shaw et ai., 1984; Rodriguez et ai., 1988) , and that gender differences disappeared by 50 to 60 years of age (Davis et aI., 1983; Shaw et ai., 1984) . A recent functional magnetic resonance imaging study in normal volunteers demonstrates a significantly greater rise in regional CBF in women compared with men during focal physiologic neural activity (Kastrup et ai., 1999) . In nor mal subjects aged 21 to 58 years, women also demon strate greater cerebral vasodilatory capacity to CO 2 than men assessed by bilateral transcrania1 Doppler sonogra phy (Kastrup et ai., 1997) . Similarly, enhanced cerebral vasodilation to acetazolamide has been reported in women versus men (Karnik et ai., 1996) . Estrogen re placement may improve perfusion in postmenopausal women with and without known cerebrovascular disease.
In one study of 14 postmenopausal women, ERT with oral conjugated estrogens increased whole cerebral and cerebellar flow, as measured by single-photon emission computed tomography (Ohkura et ai., 1995) . A larger, retrospective study of women 40 to 90 years of age used J33 Xe inhalation to assess gray matter blood flow (Funk et ai., 1991) . The ERT modestly improved perfusion and cognitive test performance among women with a history of transient ischemic attack or reversible ischemic neu rologic deficit (but had no effect on postmenopausal women with no history of cerebrovascular disease). In experimental research, direct evidence of estrogenic vasoactivity in vivo appears to be model specific and in some cases difficult to demonstrate. In basal, nonisch emic conditions, little evidence supports a tonic influ ence for estradiol on CBF. Animal studies demonstrate similar CBF values between the sexes in both anesthe tized and conscious states (Hum et ai., 1995; Alkayed et al. 1998a; Carswell et aI., 1999c; Goldman et ai., 1976) . In conscious rodents, ovariectomy per se does not influ ence basal CBF (Holshneider and Scremin, 1998), and under anesthesia, similar basal CBF values are reported in intact, OVX, and OVX plus estradiol treatment groups (Wang et ai., 1999) . Estradiol supplements did not influ ence basal CBF in intact female rabbits (Hum et aI., 1995) , and in a study on OVX sheep, infusions of physi ologic doses of 17f3-estradiol did not influence CBF acutely (2 hours), although improved flow was evident after 3 to 6 days of treatment (Magness et aI., 1998) . Finally, high-dose (10 f1g) intravenous estradiol has been measured at one time point (10 minutes after adminis tration) in conscious rats and was found to produce glob al increases in CBF in both sexes (Goldman et aI., 1976) . Vol. 20, No. 4, 2000 In ischemic conditions, estrogen-mediated improve ment in CBF has been most clearly identified in models of global or forebrain ischemia (Table 2 ). In near complete global cerebral ischemia, residual intraisch emic blood flow was greater in cerebral hemispheres and cerebellum of 17f3-estradiol-treated rabbits compared with untreated females or males (Hum et aI., 1995) . In addition, hyperemia was less during early reperfusion. However, the significance of enhanced perfusion to im proved tissue outcome was not established in this non survival protocol. Pelligrino et al. examined a range of 17f3-estradiol repletion doses in OVX rats exposed to right carotid occlusion with hemorrhagic hypotension and 72 hours of reperfusion (Pelligrino et aI., 1998) .
Here, 17f3-estradiol produced a dose-dependent preser vation of intraischemic cortical perfusion as assessed by laser Doppler flowmetry (LDF), accompanied by pre served EEG power, as well as improved histopathologic and neurologic outcome. Importantly, efficacious effects were lost at supraphysiologic doses (0.5 mg/kg/day) of 17f3-estradiol. This study offers insight into mediators by which estrogen could act in the ischemic cerebral circu lation. First, 17 f3-estradiol' s ability to preserve the in traischemic flow signal was blocked by treatment with a selective neuronal nitric oxide synthase (NOS) antago nist. Second, cortical Ca 2 + -dependent NOS activity was markedly suppressed in OVX animals and restored by estrogen treatment at all doses. However, restoration of NOS activity with high-dose l7f3-estradio1 treatment did not result in preservation of intraischemic vasodilation, suggesting that potential estrogen-NOS interactions are specific to low estrogen concentrations.
The situation is much less clear for focal cerebral isch emia. Three studies monitored CBF by cortical LDF dur ing ischemia in OVX and 17f3-estradiol-treated OVX rats (Rusa et ai., 1999; Dubal et ai., 1998; Shi et aI., 1998) . Although 17f3-estradiol significantly reduced in farct volume, there was no evidence of 17f3-estradiol mediated improvement in ischemic CBF in these studies. However, caution must be exercised in interpreting these data, since flow is monitored from only a single discrete point on the cortical surface with this technique and, therefore, flow-mediated effects of estrogen may have been missed. Shi et al. (1998) , however, report a signifi cant improvement in CBF at 1 hour of reperfusion in the 17f3-estradiol-treated animals ( Table 2) . Toung et aI., (1998) examined the influence of acute and chronic (low-and high-dose) 17f3-estradiol treatment on isch emic CBF in male rats, again with LDF. Neither acute nor chronic treatments influenced CBF during ischemia or at 30 minutes of reperfusion.
Turning to native estradiol, Alkayed et al. (1998) mea sured intraischemic CBF in males and in intact and OVX females in both normotensive (Wistar) rats and SHR-SP (Table 2 ). In both rodent strains, intraischemic CBF Estrogen's cellular signaling targets and transduction mechanisms, Estrogenic steroids use diverse mechanisms to pro duce biological effects, and its neuroprotective properties probably are multifactorial. Classic estrogen signaling (H) occurs through a nuclear receptor that acts as a ligand-activated transcription factor (RH), a protein complex that binds to a hormone-responsive element (HRE) within genomic DNA and targets transcription of mRNA and cognate protein expression, The result is enhanced or suppressed efficiency of gene transcription. There are numerous examples of estrogen's ability to upregulate gene expression, including selected members of the nitric oxide synthase (NOS) and bc/-2 families. Re cently, estrogen's activation of plasma membrane hormone recep tors and downstream intracellular signaling has been postulated (e,g" through mitogen-activated protein kinase), Such events initiate generalized signaling pathways to the nucleus or to membrane localized effectors. Evidence also indicates that the hormone can act directly at neurotransmitter receptor complexes or at ion channels (e,g" voltage-dependent calcium channels), resulting in altered neu ronal current conductance or transcellular ion flux, Crosstalk be tween nuclear activation and membrane-associated events is likely, Last, estrogen has important non-cell type-specific actions, such as antioxidation and conservation of endogenous free radical scaveng ing agents.
(measured by LDF) was significantly higher in females compared with males or OVX females. Further, using [ 14 C] iodoantipyrine autoradiography in Wi star rats to provide absolute values of flow throughout the middle cerebral artery territory, a significant elevation in isch emic flow was demonstrated in the caudate nucleus of intact females compared with the other two groups (Table 2, Fig. 7) . Carswell et al. (l999d) also examined intraischemic CBF autoradiographically in conscious SHR-SP to explore the mechanism of reduced infarct volume in proestrus (highest estradiol levels) compared with metestrus (lowest estradiol levels) in this strain. However, neither measurement of CBF in specific neu roanatomic regions nor frequency distribution analysis throughout the middle cerebral artery territory revealed any difference in ischemic CBF between the two stages of the estrus cycle (Carswell et aI., 1999c) . Therefore, in this instance, protection of brain tissue in proestrus was not mediated by flow enhancement. In summary, the flow enhancement effects of estradiol have been demonstrated convincingly in global and fore brain ischemia, but only limited evidence is available in focal cerebral ischemia. This may result from limitations of the CBF methodologies or may suggest that for focal cerebral ischemia, the protective effects of estradiol are nonvascular. Whether endogenous estrogens or pharma ceutical preparations alter CBF or microvascular dys function during reperfusion from an ischemic insult has not been well studied. Furthermore, there are numerous potential mechanisms by which estrogen acts directly on neurons or glia. Available data for vascular and selected parenchymal mechanisms are summarized in the subse quent sections, as well as potential links between the steroid hormone's cognate receptors and neuroprotection.
ESTROGENIC SIGNALING AND ROLE OF ESTROGEN RECEPTORS IN
CEREBRAL ISCHEMIA
Early autoradiographic studies using [ 3 H]-estradiol in jections clearly demonstrate numerous sites of nuclear accumulation and retention of radioactivity in brain and spinal cord of both sexes (Stumpf, 1968 ). Furthermore, estradiol binding sites have been demonstrated in vascu lar endothelium, and functional estrogen receptors (ER) are present in vascular smooth muscle. Consequently, it is not surprising that estrogen exhibits significant bio logical actions in blood vessels, neurons, and glia, many of which are likely relevant to its antiischemic properties. Recent evidence emphasizes that estrogenic steroids use diverse signaling mechanisms to produce biological ef fects. These include the following: (I) ER-linked geno mic actions; (2) non-ER-Iinked transcriptional mecha nisms that use generalized signaling molecules; (3) ER dependent, nontransciptional mechanisms; and (4) cell membrane associated activity, which clearly does not depend on messenger RNA (mRNA) transcription and protein synthesis (Fig. 8) . Classically described estrogen signaling occurs through a nuclear ER that acts as a ligand-activated transcription factor, a protein complex that binds to a hormone-responsive element within ge nomic DNA and alters transcription of mRNA and cog nate protein expression. Therefore, activation of classic ER signaling results in enhanced or suppressed modula tion of target gene transcription efficiency, and there are numerous examples of estrogen 's genomic actions in ste roid-responsive tissue. Furthermore, hormone response elements for estrogen, or consensus palindromic DNA sequences, are present on many mammalian genes not necessarily associated with reproductive function, for ex ample, the gene for constitutive NOS (Venema et al., 1994) .
Other signaling mechanisms have been described that differ from this classic schema. For example, estrogen may act through the cAMP pathway to regulate cAMP mediated gene transcription or to alter transcription of estrogen-regulated genes (Katzenellenbogen, 1996; Wat ters and Dorsa, 1998) . Furthermore, although estrogen has been depicted as a transciptional hormone, there are known nontransciptional effects that occur through rapid cell membrane-associated activity with (Shaul et aI., 1999; Goetz et aI., 1999) or without input from known ER (Tischkau and Ramirez, 1993; Mermelstein et aI., 1996) . Some of these rapid actions involve membrane and intracellular receptors, which are coupled by second messengers to ion channels and to neurotransmitter re ceptors (Mermelstein et aI., 1996; Ross et aI., 1999) , or involve membrane-localized enzymes such as endotheli al NOS (Goetz et aI., 1999; Chen et aI., 1999) . Compre hensive reviews of these topics are found elsewhere (Farhat et ai., 1996; Ross et aI., 1997; Revelli et aI., 1998; Woolley and Schwartzkroin et aI., 1998) .
Few data distinguish which of these diverse signaling mechanisms are used by estrogen in its protective actions during stroke and cerebral ischemia. Limited data ad dress the relative importance of ER or transcriptional dependence. Two ER subtypes have been characterized: ERa and, recently, an ERI3 subtype (Kuiper et aI., 1996 (Kuiper et aI., , 1997 Mosselman et aI., 1997) . These isoforms differ in the C-terminal ligand binding domain and in the N terminal trans-activation domain. There are no known subtype-selective antagonists; however, general ER an tagonists, such as tamoxifen and the steroid ICI family (e.g., ICI 182,780), block estrogen's actions in a tissue specific manner by inhibiting ER-initiated gene activa tion (Kangas, 1992) . Most clues as to the role of ER come from paradigms that used general ER antagonists or 17a-estradiol, a relatively inactive estrogen that does not bind to known ER. Furthermore, some inferences about lack of ER relevance have been drawn from posi tive results obtained only in the presence of pharmaco logic estrogen doses and concentrations that saturate re-ceptor binding (e.g., micromolar concentrations). With regard to estrogen and cerebral ischemia, several in vitro investigations use ER antagonists or protein synthesis inhibitors to evaluate ER-initiated transcriptional activ ity. These reports are summarized in subsequent sections addressing specific vascular or parenchymal mecha nisms. In addition, several in vivo studies address the issue of whether estrogen's neuroprotective effects in stroke are mediated by ER (Simpkins et aI., 1997 ; Hum et aI., 1998 , Sawada et aI., 1999 . Using a rat MCAO model, Simpkins et al. report that pretreatment with sub cutaneous implants containing 17 a-estradiol reduced in farction volume equivalently to the same dose of the 1713 isomer. Notice that large doses of both 17 a-and l3-es tradiol were used, and although plasma steroid levels were not reported, it is likely that supraphysiologic con centrations resulted. Nevertheless, the efficacy of 17a estradiol suggests that estrogen's neuroprotection was not likely mediated by nuclear ER signaling. This is an important finding when taken in context of pharmaco logic neuroprotection. Further studies are needed to dem onstrate if estrogen's effects are receptor independent over the range of estradiol doses currently shown to be effective in experimental stroke. Two further studies evaluate whether endogenous estrogen acts through ER mechanisms in transgenic and wild-type mice treated with MCAO (Hum et aI., 1998a , 1998b Sawada et aI., 1999) . First, chronic treatment with the pure ER antago nist, ICI 182,780, increased infarction volume in striatum by approximately 30% in female C57Bl/6J mice com pared with vehicle-treated controls. No effects on end ischemic CBF were observed in any brain region. The deleterious effect of ICI 182,780 was notably restricted to striatum, and the distribution of ER, either subtype a or 13, within this region is under active investigation (Couse et aI., 1997 ; Shughrue et aI., 1997 ; Osterlund et aI., 1997) . Further, loss of estrogen-ER signaling was limited to intact females with circulating native estrogen, and no effect was observed in age-matched males. In a companion study, outcome from MCAO was evaluated in transgenic mice deficient in the a receptor subtype (Korach, 1994; Hum et aI., 1998) . Infarction volume was not exacerbated in these mice compared with wild-type females, suggesting that ERa is not important in estro gen's antiischemic properties. Whether the recently iden tified ERI3 subtype plays a role in stroke remains to be tested.
In summary, in vivo data examining the role of ER subtypes and the efficacy of pharmacologic estrogen preparations are limited, particularly at doses that simu late the physiologic condition. Estrogen receptors may play a regionally restricted role in protecting the female brain with endogenous estrogen during experimental stroke; however, the relative receptor subtype distribu- Vol. 20, No. 4, 2000 tion within the region of interest is likely a determining factor.
VASCULAR MECHANISMS
Much evidence obtained in noncerebral vessels sug gests that estrogen improves vasodilatory capacity and alters vessel responses to several well-studied vasodila tor and vasoconstrictor agents (for previous reviews see Mendelsohn and Karas, 1994; White et aI., 1995; Duck les et aI., 1996; Farhat et aI., 1996) , Data in cerebral vessels are limited, but those available support this con cept. The precise signaling mechanisms by which estro gen alters blood flow or vascular reactivity are poten tially diverse, Estrogen receptors have been located in vascular smooth muscle (Harder and Coulson, 1975; Karas et aI., 1994) and in endothelial cells (Colburn and Buonassisi, 1978) . Therefore, transcriptional mecha nisms may be involved. One prevailing hypothesis is that estrogen amplifies release of vasodilators, in part be cause there are estrogen response elements on the genes for endothelial and inducible NOS and for prostacyclin synthetase (Xie et aI., 1992 , Chartrain et aI., 1994 Ven ema et aI., 1994; Mendelsohn and Karas, 1994) . Rapid vasomotor effects, independent of gene activation, have been reported both in vivo and in vitro, mediated by intracellular second messengers such as Ca 2 + and the cyclic nucleotides (for review, see Farhat et aI., 1996a Farhat et aI., , 1996b . Crosstalk between membrane-mediated events and nuclear receptor activation also is likely within the vasculature (for reviews, see Mendelsohn and Karas, 1994; Baysal and Losordo, 1996) .
The coronary, uterine, aortic, and peripheral vessel literature provides evidence that estrogen influences mUltiple aspects of vessel function and disease by tar geting vascular smooth muscle cells, endothelium, and platelets. There is evidence for the following: reduction of vascular smooth muscle proliferation under baseline conditions (Moraghan et aI., 1996) and in response to balloon injury (Sullivan et aI., 1995) ; prevention of neo intimal thickening after vessel injury (White et aI., 1997 ; Oparil et aI., 1997) and atheromatous changes over time (Baron et aI., 1998) ; maintenance of endothelial struc ture, elaboration of growth factors (Schnaper et aI., 1996; Albuquerque et aI., 1998) , and reduction of endothelial apoptosis (Alvarez et aI., 1997) ; reendothelialization af ter injury (White et aI., 1997) ; and activation of vascular smooth muscle K + channels (White et aI., 1995;  Well man et aI., 1996; Darkow et aI., 1997) and inhibition of vascular smooth muscle contractility by blocking Ca 2 + influx through voltage-dependent calcium channels and enhancing efflux (Collins et aI., 1993; Shan et aI., 1994; Freay et aI., 1997; Prakash et aI., 1999) , Increased pro duction and activity of vasoactive endothelial-derived products with estrogen exposure have been widely re-ported in cultured endothelium, intact vessels, and in systemic plasma assays. The most prominent products are nitric oxide (NO) (Hayashi et al., 1992; Rosselli et aI., 1994; Hayashi et aI., 1995; Hishikawa et aI., 1995; Bell et aI., 1995; MacRitchie et aI., 1997; Cau1in-Glaser et aI., 1997; Vagoni et aI., 1998; Knot et aI., 1999) and eicosanoids, specifically prostacyclin (Mikkola et aI., 1995 (Mikkola et aI., , 1996 Myers et aI., 1996; Bolego et aI., 1997; Jun et aI., 1998) . Most of these reports agree that the elabo ration of these vasodilators is mediated through the ER. Lastly, estrogen availability reduces leukocyte adhesion in cerebral venules in vivo (Santizo and Pellegrino, 1999) , alters platelet aggregation in cerebral microves sels (Rosenblum et aI., 1985) , and reduces vasomotor responsivity to autogenous platelets in coronary vessels (Miller et aI., 1999) . There are gender differences in platelet release of cyclooxygenase metabolites of arachi donic acid and serotonin; estrogen deficiency results in enhanced platelet release of serotonin, prostacyclin, and thromboxane A 2 (Miller et aI., 1999) .
Lack of endogenous estrogen impairs vascular reac tivity, at least in noncerebral vessels. For example, en dothelium-dependent vasodilation is impaired in aortic and femoral tissue from OVX animals and restored with chronic exogenous estrogen (Gisclard et aI., 1987) . Fur thermore, estrogen partially restores dilator responses to acetylcholine in atherosclerotic monkey coronary arter ies, whereas ovariectomy produces paradoxic constric tion (Williams et aI., 1990) . Ethinyl estradiol adminis tration acutely attenuates abnormal coronary artery re sponses to acetylcholine in women (Reis et aI., 1994) , and estrogen also modulates selected vasoconstrictor stimuli and may therefore alter the net balance of vaso motor signals toward dilation under some conditions. Ex amples include estradiol's depression of vasoconstriction to endothelin-l (Jiang et aI., 1992) and to the throm boxane mimetic U46619 in coronary vessels (Thompson and Weiner, 1997) . Similarly, estrogen depresses adren ergic responsiveness, that is, vasoconstriction to norepi nephrine in noncerebra1 vascular beds by mechanisms involving alterations in adrenergic receptor affinity and expression, modification of catecholamine release, up take, and neural efflux (Hamlet et aI., 1980; Colucci et aI., 1982; McNeill et aI., 1996; Li et aI., 1997; McNeill et aI., 1999) , or by decreasing adrenergic sensitivity by increasing the basal release of relaxing factors from the endothelium (Meyer et aI., 1997) . Whether similar ef fects occur in the cerebral circulation is unclear. Al though estrogen had no effect on noradrenergic perivas cular innervation in rabbit basilar artery, chronic treat ment reduced serotonin immunofluorescence in this preparation, and estrogen withdrawal increased vasore activity to serotonin in basilar artery rings (Dhall et aI., 1988; Futo et aI., 1992) .
Although there are substantial data that estrogen in-creases eicosanoid production in the vasculature, it is not clear if this is an important vasodilator mechanism under physiologic or ischemic conditions. Physiologic concen trations of I 7 [3-estradiol increase prostacyclin produc tion and biosynthetic activity in aortic smooth muscle culture (Chang et aI., 1980; Wakasugi et aI., 1989) and in intact aortic rings as measured by elevated levels of 6-ke toprostaglandin FI a (Wakasugi et aI., 1989; Bo1ego et aI., 1997) . Similarly, estradiol increases 6-ketoprosta glandin F I a production in human and animal aortic en dothelial cells specifically at physiologic concentrations (Myers et aI., 1996) , and the effect can be prevented by tamoxifen treatment (Mikkola et aI., 1995 (Mikkola et aI., , 1996 . Fur ther, cyclooxygenase-1 is induced by estrogen in fetal pulmonary artery endothelium and by pregnancy in uter ine artery, again inhibitable by ER antagonists (Jun et aI., 1998; Janowiak et aI., 1998) . However, estradiol also may stimulate production of contractile prostanoids, since the steroid augments endothelium-dependent con traction to arachidonic acid in rabbit aorta (Miller and Vanhoutte, 1990) . The possibility that estrogen acts on more than one eicosanoid pathway has not been well studied, and it is likely that interaction among endothe lium-derived mediators is complex (Barber and Miller, 1997) . Cytochrome P-450 products and free radicals may be linked as mediators of estrogen's effects on vascular behavior (Harder et aI., 1994; Hayashi et aI., 1992) . In a variety of experimental models, gender and es trogen effects on the endothelium have been linked to NO. Estrogen increases NO availability, possibly by up regulating Ca 2 + activated, endothelial NOS (Weiner et aI., 1994) or inducible Ca 2 +-independent NOS (Binko and Majewski, 1998) , by increasing substrate availability for NO formation (Kauser and Rubanyi, 1997) , or by limiting the inactivation of NO as a substrate in other reactions (Arna1 et aI., 1996; Kauser and Rubanyi, 1997) . In noncerebral vessels, at least one of estrogen's vaso motor mechanisms involves NO/cGMP/protein kinase G signaling (Stice et aI., 1987; Magness et. aI, 1991; Wellman et a!., 1996; Darkow et aI., 1997) . Further, data from coronary vessels suggest that estro gen's downstream effector in this signal transduction pathway is vascular smooth muscle voltage-activated K+ channels. White et a!. have shown that 17[3-estradiol re laxes coronary arteries in vitro in an endothelium independent manner, opening large conductance, cal cium and voltage-activated K+ channels (BK C a) through cGMP-dependent phosphorylation . Further, gender-specific myogenic tone in coronary ves sels is estrogen-and endothelium-dependent and can be inhibited by ER antagonists such as tamoxifen (Wellman et a!., 1996) . This latter study also offers evidence that the signaling pathway involves activation of BK C a in vascular smooth muscle cells by protein kinase G. Notice that the protein kinase G-BK C a mechanism is a known signaling pathway in brain (Yao et aI., 1995) and cere bral vascular smooth muscle (Braydon and Nelson, 1992; Robertson et aI., 1993) and can serve as a "vasomotor effector" common to both endothelium and smooth muscle derived vasodilators. From the limited data avail able, high conductance, calcium-activated K + channels did not mediate estrogen's effect in the cerebral circula tion, in contrast to findings reported in coronary vessels (Wellman et aI., 1996) . Passive mechanical properties were similar among vessels, regardless of estrogen avail ability, suggesting that estrogen did not alter vessel wall composition in these young, adult animals. Myogenic tone differences induced by estrogen also may be vessel size dependent (Geary et aI., 1996) .
Ovariectomy does reduce the pial microvascular re sponse to topical acetylcholine in situ but does not alter vasodilation to the direct NO donor S-nitroso-N-acetyl penicillamine, suggesting a lack of direct effect on vas cular smooth muscle (Pelligrino et aI., 1997) . Chronic 17[3-estradiol treatment also elevates basal cerebral mi crovascular cGMP content, although the effect is re stricted to high doses of pharmacologic rather than physiologic relevance (Palmon et aI., 1998) . Geary et aI. examined pressurized cerebral resistance vessels (280-to 300-J.Lm diameter) and documented essential gender dif ferences in myogenic tone (Geary et aI., 1998) . Further more, 17[3-estradiol treatment was associated with re duced tone and increased vascular distensibility, acting by a NO-dependent mechanism. In the presence of � nitro-L-arginine methyl ester, middle cerebral artery re sponse to increased transmural pressure in female or es trogen-treated tissue mimiCked that of estrogen-deficient tissue from males or OVX females. In summary, estro gen is well established as a vasodilator in many regional beds, ahd available data suggest that the steroid has vas cular activity within the cerebral circulation. Such activ ity may include direct vasodilation, enhanced vasodila tory capacity through increased elaboration of NO, pros tacyclin-or other endothelium-derived mediators, and reduced sensitivity to selected vasoconstrictor stimuli such as endothelin-l, norepinephrine, and thromboxane. Although the mechanisms remain to be elucidated, in certain circumstances endogenous estrogen can partially restore intraischemic CBF. Limited data are available that evaluate interactions between pharmacologic estro gen preparations and vascular mechanisms of neuropro tection.
PERFUSION-INDEPENDENT MECHANISMS
OF PROTECTION
The ability of estrogen to protect neurons by perfu sion-independent mechanisms is illustrated in both tissue culture experiments (Goodman et aI., 1996; Regan et aI., 1997) and in in vivo studies, where the ischemic insult is J Cereb Blood Flow Metab, Vol. 20, No. 4, 2000 controlled to produce the same level of ischemia in con trol, OVX, and estrogen-treatment groups (Wang et aI., 1999) . Estrogen has direct and rapid effects on neuronal tissue. For example, synaptic architecture within areas such as hippocampus changes with the estrous cycle and can be altered in less than 24 hours by exogenous estra diol (Woolley et aI., 1992) . Complementary fluctuations in the volume of astrocytic processes and synaptic num bers also occur in response to ovarian steroids (Klintsova et aI., 1995) , and ER have been localized on glial cells (Azcoitia et aI., 1999) . Therefore, perfusion-independent mechanisms involving neurons or glia are likely in volved in estrogen's ability to reduce ischemic brain in jury. Potential mechanisms include antioxidant actions, induction of neuroprotective gene products such as bcl-2 and neurotrophic growth factors, and nontranscriptional modulation of excitatory neurotransmission and conse quent glutamate toxicity (Fig, 8) ,
Antioxidant activity
Many estrogens have well-established and potent lipid antioxidant activity, particularly the catechol estrogens (2-hydroxy estrone and 2-hydroxy estradiol) and, to a lesser extent, phenolic estrone and 17 [3-estradiol (Na kano et aI., 1987; Mukai et aI., 1990; Mooradian, 1993) . Culmsee et al. (1999) have demonstrated that Fe 2 + _ induced levels of reactive oxygen species and neurotox icity were significantly attenuated by low micro molar concentrations of 17[3-estradiol and 2-hydroxy estradiol in chick embryonic neurones, even in the presence of the ER antagonist tamoxifen. Given these data, several in vestigators have hypothesized that estrogen decreases oxygen radical-induced brain injury by direct radical scavenging action or through preservation of endogenous antioxidants. The distinction between these two different mechanisms appears to be linked to steroid concentration within the experimental system. In vitro studies in hip pocampal cell lines, primary hippocampal culture, and organotypic slices have demonstrated that estrogen treat ment at supraphysiologic concentrations (i.e., greater than 10-9 mollL) reduced neuronal death after prooxi dant and amyloid [3-peptide exposure (Goodman et aI., 1996; Behl et aI., 1997) . Further, 17[3-estradiol and eq uilin (an equine mixture of estrogens) protected against DNA damage induced by hydrogen peroxide or arachi donic acid (Tang and Subbiah, 1996) . Direct radical scavenging action thus may predominate in estrogen's neuronal protection at pharmacologic concentrations, since this activity was observed only at high estradiol concentrations in male gerbils treated with forebrain ischemia. However, sparing of hippocampal neurons was observed at near-physiologic doses (Sudo et aI., 1997) . Others report good protection against trophic factor with drawal and amyloid [3-peptide by estradiol at micro molar concentrations in PC12 cells. This was accompanied by a suppression of mitochondrial reactive oxygen species and preservation of mitochondrial function . Pretreatment of cortical synaptosomes with 17fj-estradiol also suppressed membrane lipid peroxida tion induced by amyloid fj-peptide and iron (Keller et aI., 1997) . In contrast, superoxide anion production was re duced in aortic endothelial cells by ethinylestradiol treat ment with a physiologically relevant ECso of 0.1 nmol/L (Arnal et aI., 1996) . This effect resulted in significant preservation of endothelium-derived NO bioactivity and was completely prevented by ER antagonists. Therefore, the capacity of estrogen to prevent oxidative damage may differ among the different cell types exposed to the intense ischemia associated with a stroke. Effective protection, associated with a requirement for phenolic A ring structure, also has been demonstrated at physiologically relevant concentrations (Green et aI., 1997) and with decreased lipid peroxidation (Gridley et aI., 1997) in neuroblastoma cell lines. Subsequent work from this same group indicates that estrogen's protection at physiologic levels in cortical neurons relies on syner gism with reduced glutathione by an ER-independent mechanism (Gridley et aI., 1998; Green et aI., 1998) . Estrogen or glutathione had no independent effect on cell survival; however, the ECso for estradiol was favorably shifted in the presence of glutathione (Gridley et aI., 1998) . Conservation of endogenous antioxidants by es trogen is a recurring finding in animal studies. In the intact female animal or in females treated with physi ologic hormone replacement, vitamin E and ascorbate are spared during ischemic stress, whereas enhanced oxi dant stress and depletion of antioxidants was observed in males and OVX animals (Hall et al., 1991; Kume-Kick et aI., 1996; Kume-Kick and Rice, 1998) . Further, baseline regional brain ascorbate levels were higher in female versus OVX or male rats. The gender difference was apparent after onset of puberty and largely lost in aged animals (Kume-Kick and Rice, 1998) .
Interaction with bcl-2
Estrogen has been linked to an important set of neu roprotective proteins, the protooncogene bcl-2 family, which has been extensively implicated in cell survival in models of cerebral ischemia and apoptosis. In normal reproductive tissue, the steroid induces and supports bcl-2 expression and suppresses cyclical cell death (Sa bourin et aI., 1994; Tilly et aI., 1995) . For example, estrogen induces bcl-2 in normal breast tissue in a phasic manner over the estrous cycle (Sabourin et aI., 1994) and supports constitutive bcl-2 and bcl-x-l expression during follicle development in the ovary (Tilly et aI., 1995) . Bax levels also are decreased, improving the bcl-2/Bax ratio (Tilly et aI., 1995) . In both tissues, estrogen suppresses cell degeneration and loss. Similar effects can be ob served in injured or pathologic tissue. Human breast can-cer cell lines strongly express bcl-2 in response to estro gen and ER activation, resisting cell death and chemo therapeutic agents (Teixeira et aI., 1995) . Apoptosis of aortic endothelial cells after injury is attenuated by ex ogenous estrogen (Spyridopoulos et aI., 1996) . If bcl-2 is richly expressed in steroid-sensitive brain under basal or postischemic conditions, then tissue sparing could result. Several reports support this hypothesis. First, estrogen treatment increases bcl-2 expression in NT2 cells with neuronal phenotype, a mechanism that may account for estradiol's neuroprotective activity when these cells are exposed to glutamate or hydrogen peroxide (Singer et aI., 1998) . Second, bcl-2 expression varies with the estrus cycle in rat hypothalamic neurons, as measured by in situ immunohistochemical study. Further, bcl-2 protein was decreased by ovariectomy but responsive to hormone replacement in the adult female brain (Garcia-Segura et aI., 1998) . Third, in experimental stroke, bcl-2 mRNA is enhanced in penumbral areas to a greater extent in fe male or estradiol-treated rats than in estrogen-deficient animals (Alkayed et aI., 1998) . A more recent report demonstrates that not only was estradiol treatment asso ciated with increased bcl-2 mRNA in injured cortex, but its expression was paralleled by increased levels of ER transcripts (Dubal et aI., 1999) . These data suggest that one mechanism by which estrogen acts to reduce stroke damage in animals is through receptor-mediated, en hanced bcl-2 transcription. Whether this mechanism is brain region-or cell type-specific remains to be dem onstrated.
Signaling through growth factors
Estrogen is a growth-or neurite-promoting factor, in its own right, in the mammalian brain (Lustig et aI., 1991; Toran-AIIerand, 1996a , 1996b . The hormone en hances growth and arborization of neuronal processes, both axonal and dendritic, primarily during development. In the mature brain, axotomy or deafferentation-type in juries in steroid-sensitive regions of the brain also re spond to estrogen treatment (Matsumoto and Arai, 198 1 ) , and the loss of the trophic effects of estrogen with ovariectomy (Gould et aI., 1990) can be reestablished by estrogen treatment. The result is formation of new syn apses, dendrite differentiation, and increased dendritic spine density. Although the mechanism is controversial, it is likely that these actions occur in combination with endogenous growth factors (Chalbos et aI., 1994; Toran Allerand, 1996a , 1996b . One theory is that estrogen acts indirectly through increasing gene transcription or activ ity of estrogen-responsive peptide growth factors, which in turn act on neighboring cells through autocrine or paracrine mechanisms. There is also considerable evi dence to implicate the ER in signaling crosstalk between hormones and growth factors in brain under physiologic conditions (Toran-Allerand, 1996b; KatzeneJlenbogen, 1996) . Many of the growth factors linked to estrogen signaling also have clear neuroprotective and regenera tive properties in brain. These include nerve growth fac tor (Gibbs et aI., 1994; 1998) , brain-derived neurotrophic factor and other neurotrophins (Singh et aI., 1995; So hrabji et aI., 1995; Toran-Allerand, 1996a , 1996b Mur phy et aI., 1998) , insulin-like growth factor-I (Fernandez Galaz et a!., 1997), and the fibroblast growth factor fam ily (in particular, bFGF; Takahashi and Nakagawa, 1997) . Therefore, estrogen may act in concert with these peptides, or through their signaling pathways, to preserve neuronal survival after injury or even to promote neuro genesis in the adult brain (Tanapat et aI., 1999) .
Reducing excitotoxic-ischemic damage
A large body of literature indicates that estrogen alters both glutamatergic and 'Y-aminobutyric acid (GABA) ergic neuronal activity in many steroid-sensitive brain regions. Therefore, the steroid may blunt excitotoxic cas cades that are important mechanisms of injury in stroke. Behaviorally and morphologically, female animals are more sensitive than males to the adverse effects of N methyl-D-aspartate (NMDA) receptor antagonists such as MK801, suggesting greater susceptibility to NMDA re ceptor blockade in females and sex-related differences in the endogenous modulation of this glutamate receptor subtype (Honack and Loscher, 1993; Akinci and Johns ton, 1993; Auer, 1996) . Estradiol prevents neuronal loss resulting from kainic acid injection into dentate gyrus (Azcoitia et aI., 1998) . Further, estrogen directly blocks kainate (Regan and Guo, 1997) and glutamate (Behl et aI., 1995; Goodman et a!., 1996; Singer et aI., 1996 Singer et aI., , 1999 injury in vitro, as assessed in hippocampal and cortical neuronal cultures. Protective effects were hor mone-specific in these latter studies; lesser protection was present with progesterone, and other steroids had no effect. The mechanism of protection may be linked to reduction of NMDA-induced calcium influx, since estro gen is known to modulate intracellular calcium through other types of ionotropic channels (Weaver et a!., 1997; Mermelstein et a!., 1996) . Alternatively, estrogen may stimulate mitogen-activated protein kinase signal transductive pathways to protect cells in a similar way as growth factors (Singer et aI., 1999) .
Female reproductive steroids also may ameliorate ischemic injury through promotion of GABAa receptor mediated mechanisms, as well as through suppression of excitatory amino acid toxicity. Increases in extracellular glutamate, GAB A, and glycine levels have been well documented in all models of cerebral ischemia, support ing the concept that it is the imbalance between excita tion and inhibition that ultimately determines neuronal injury and death (Globus et aI., 1991; Lin et a!., 1992) . Globus et aI. demonstrated that an excitotoxic index de rived from glutamate, GABA, and glycine concentra-J Cereb Blood Flow Metab, Vol, 20, No, 4, 2000 tions can be a primary predictor of injury after transient cerebral ischemia (Globus et aI., 1991) . The potency of estrogen and progesterone on GABAergic signaling var ies selectively across brain region and is under intense investigation (for reviews see Smith, 1989; Paul and Purdy, 1992; McCarthy, 1995) . Both reproductive ste roids have been reported to alter GABA conduction (Ma jewska, 1992) , induce synaptosomal and hippocampal GABA release (Fleischmann et aI., 1990; Tauboll et aI., 1993) , upregulate GABAa receptor number (Weiland and Orchinick, 1995; Canonaco et aI., 1989; Juptner et aI., 1991; Maggi and Perez, 1986) , increase GABAa agonist binding affinity (Schumacher et a!., 1989; Jussofie et a!., 1995) , and alter glutamic acid decarboxylase mRNA (Weiland, 1992; McCarthy et aI., 1995; Grattan et aI., 1996; Davis et aI., 1996) . Estrogen administration to OYX females increases brain GABA levels (Luine et aI., 1997) and increases agonist binding at the GABAa re ceptor within hours, particularly in cortex and striatum (Maggi and Perez, 1986) and less so in hippocampus (Schumacher et aI., 1989) . The functional significance of these events to neuroprotective mechanisms in brain re mains to be shown.
CONCLUSION
This review summarizes gender-specific aspects of clinical and experimental stroke, the favorable results of estrogen treatment in animal models, and potential vas cular and parenchymal mechanisms of neuroprotection. Premenopausal women may thus be protected in part from stroke, with reproductive hormone status playing a significant role in this gender-linked protection. Stroke and cerebrovascular disease history should be considered in the individual's decision to use HRT during the post menopausal years. Animal studies clearly indicate that gender is one additional factor that influences experi mental stroke outcome and that estrogen is an effective neuroprotectant in both male and female brain. This new concept suggests that further dissection of the interac tions between reproductive steroids and cerebral isch emia will continue to yield novel insights into general ized cellular mechanisms of stroke and therapy. Numer ous experiments are needed to determine fully the steroid's therapeutic window of activity, optimal dose response relationships, and flow-dependent and flow independent cellular and molecular mechanisms.
